Revenue and Financial Performance - Revenue and net earnings are typically higher in the third and fourth fiscal quarters, with the first quarter generating the lowest revenue and the last quarter the highest, primarily due to seasonality in operational maintenance, pharmaceutical and biotechnology spending, and product demand[68] - The company's backlog as of June 30, 2024, was 2.34billion,comparedto2.53 billion in 2023, with 78% expected to be recognized as revenue by the end of fiscal 2025[70] - The company has invested 1.56billioninmanufacturinganddevelopmentfacilitiessincefiscal2022,including327 million in capital expenditures during fiscal 2024[73] Operational Excellence and Delivery - The company achieved approximately 96% on-time shipment delivery in fiscal 2024, driven by operational excellence and process standardization[74] - Research and development costs were 17million,18 million, and 23millionforfiscal2024,2023,and2022,respectively[78]WorkforceandEmployeeEngagement−AsofJune30,2024,thecompanyhadapproximately16,900employeesglobally,withwomenrepresenting441.25 million in fiscal 2023[101] - 21% of employees participated in the annual Month of Service in fiscal 2023, up from 18% in fiscal 2022[101] - The company closed the U.S. gender pay gap in fiscal 2021 through EDGE certification[102] Intellectual Property and Quality Management - Catalent holds more than 2,100 patents and patent applications worldwide[110] - The company has implemented a global quality management system with employees worldwide focusing on quality and regulatory compliance[115] - The company's facilities are subject to periodic inspections by the FDA, DEA, and other regulatory authorities, with all inspection observations resolved or on track for completion[115] - The company's operations are in compliance with environmental, health, and safety regulations, with appropriate reserves recorded for potential liabilities[118] Financial Risks and Exposure - The company is exposed to interest rate fluctuations on 500millionofU.S.dollar−denominatedtermloans,withthevariableportioneffectivelyfixedat0.94319 million[378] - The company is exposed to foreign exchange rate fluctuations, with principal drivers including the European euro, British pound, Argentinean peso, and Brazilian real[379] - The company's foreign currency exposure includes transactional and translational risks, with financial statements of foreign operations translated into U.S. dollars using period-end exchange rates[379] - Foreign currency transaction gains and losses are included in the statements of operations, utilizing weighted average exchange rates for the period[379]